Narashino

Researchers are evaluating MK-2214, a study treatment designed to slow brain changes in people with early Alzheimers disease AD. AD is a form of dementia that causes memory loss, communication difficulties, and challenges in decision-making, affecting daily tasks. This phase 2 trial aims to determine if MK-2214 slows the spread of tau protein in the brain compared to a placebo, as well as to assess the safety and tolerability of MK-2214. Participants will be randomly assigned to receive either MK-2214 or a placebo through intravenous IV infusion every 4 weeks during the study. The study uses a parallel design with quadruple masking to compare the effects of the study drug versus placebo over a period of up to approximately 23 months. Both groups receive infusions on the same schedule to maintain the studys integrity. During the study, participants will undergo brain scans including positron emission tomography PET to measure tau protein levels and other assessments such as cognitive and daily living function tests. Researchers will monitor adverse events and treatment discontinuations throughout the study, which lasts up to about 26 months. These assessments help determine the impact of MK-2214 on disease progression and safety in individuals with early AD.

This research aims to evaluate how well and safely orforglipron works in adult female participants with stress urinary incontinence SUI who also have obesity or are overweight. SUI is a condition where urine leaks during activities such as coughing or exercising. The study is a Phase 3 clinical trial conducted under a master protocol supporting two independent studies, focusing on this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo, both given orally once daily. The study uses a double-blind design with parallel groups to compare the effects of orforglipron against placebo. The treatment period lasts approximately 52 weeks, followed by safety follow-up, making total participation about 58 weeks from screening to study completion. During the study, participants will undergo assessments including measuring changes in the frequency of incontinence episodes, body weight, quality of life related to urinary incontinence, use of continence pads, and cholesterol levels. Researchers will monitor waist circumference and patient impressions of their condition as well. Safety follow-up continues after treatment to ensure participant well-being throughout the study duration.

Researchers are evaluating the effects of Treprostinil Palmitil Inhalation Powder TPIP on adults with pulmonary hypertension associated with interstitial lung disease PH-ILD. The study aims to compare 24 weeks of once-daily TPIP treatment versus placebo to assess changes in exercise capacity and other health measures. This phase 3, randomized, double-blind, placebo-controlled trial seeks to better understand the treatments impact on this condition. Participants will be randomly assigned to receive either TPIP starting at 80 micrograms daily, with doses increased up to a maximum tolerated dose of 1280 micrograms, or a placebo inhaled once daily for 24 weeks. Both treatments are delivered via a capsule-based dry powder inhaler device. The study is conducted across multiple centers and includes careful monitoring of drug levels and health outcomes over the treatment period. During the study, participants will undergo assessments including the six-minute walk distance test to measure exercise capacity, blood tests to evaluate heart strain markers, and symptom questionnaires related to pulmonary fibrosis. Researchers will monitor safety, treatment adherence, and clinical events throughout the 24 weeks. The trial will also track time to clinical worsening and major health events, with detailed evaluations at baseline and regular intervals until the study ends.